Maxim Group Downgrades Virpax Pharmaceuticals to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group has downgraded Virpax Pharmaceuticals from Buy to Hold, indicating a change in the analyst's outlook on the company's stock.
October 09, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Maxim Group has downgraded Virpax Pharmaceuticals from Buy to Hold, suggesting a less optimistic view on the stock's potential performance.
The downgrade from Buy to Hold by Maxim Group indicates a shift in the analyst's perspective, potentially leading to a negative short-term impact on VRPX's stock price as investors may reassess their positions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100